New drug aims to preserve sight in rare genetic blindness
NCT ID NCT07290530
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether NPI-001, taken twice daily for 24 months, can slow the loss of light-sensing cells in the eyes of adults with Usher syndrome, a genetic condition that causes both hearing and vision loss. About 80 participants will receive either the drug or a placebo. The study measures changes in the area of healthy retina over time and tracks any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA (RP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an antioxidant pill slow blindness in usher syndrome?
- Thousands join fight against blindness by sharing their stories
- Eye zap study seeks to prove what patients already feel
- Can an arthritis drug save sight? small trial tests adalimumab for rare eye diseases
- Could a blood extract save sight? early trial tests PRP for rare eye diseases
- Brain zaps may boost mobility in the visually impaired